Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.65 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18668643 | 1.00 | CA2 (0.65) | CA2GPR119USP30CHRNA7CA12 | |
| SCHEMBL18668645 | 1.00 | CA2 (0.65) | CA2GPR119USP30CHRNA7CA12 | |
| SCHEMBL23620982 | 0.82 | GPR119 (0.52) | CA2GPR119CHRNA7CA12CA1 | |
| SCHEMBL18668482 | 0.81 | CA2 (0.56) | CA2GPR119USP30CHRNA7CA12 | |
| SCHEMBL20398030 | 0.79 | CA2 (1.00) | CA2CA12CA1CA7 | |
| SCHEMBL18668733 | 0.79 | CA2 (1.00) | CA2CA12CA1CA7 | |
| SCHEMBL18689042 | 0.79 | CA2 (1.00) | CA2CA12CA1CA7 | |
| SCHEMBL20398094 | 0.78 | CA2 (0.57) | CA2CHRNA7CA12CA1CA7 | |
| SCHEMBL20398095 | 0.78 | CA2 (0.57) | CA2CHRNA7CA12CA1CA7 | |
| SCHEMBL29963379 | 0.78 | CA2 (0.57) | CA2CHRNA7CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115124538-A | Bicyclic compounds as ATX inhibitors | 豪夫迈·罗氏有限公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-3353180-B1 | BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN LA ROCHE (CH) | 2022-03-16 | — | — | EP | disclosed |
| EP-3353181-B1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-11 | — | — | EP | disclosed |
| US-10889588-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10787459-B2 | Bicyclic compounds as ATX inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200291038-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10738053-B2 | Bicyclic compounds as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200079779-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-03-12 | — | — | US | disclosed |
| US-20180208602-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180208601-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208602-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN10, ATXN2L | CA2 3500/4885GPR119 1521/4885USP30 2930/4885 |
| US-20200079779-A1 | NEW BICYCLIC COMPOUNDS AS ATX INHIBITORS | ATXN2, ATXN10, ATXN2L | CA2 3500/4885GPR119 1521/4885USP30 2930/4885 |
| US-10787459-B2 | Bicyclic compounds as ATX inhibitors | ATXN2, ATXN10, ATXN2L | CA2 3341/4885GPR119 1762/4885USP30 2724/4885 |
| US-20180208601-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | CA2 215/4885GPR119 2746/4885USP30 2043/4885 |
| US-20200291038-A1 | BICYCLIC COMPOUNDS AS DUAL ATX/CA INHIBITORS | ATXN2, ATXN2L, ATXN10 | CA2 215/4885GPR119 2746/4885USP30 2043/4885 |
| US-10738053-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | CA2 215/4885GPR119 2746/4885USP30 2043/4885 |
| US-10889588-B2 | Bicyclic compounds as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | CA2 215/4885GPR119 2746/4885USP30 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.